JP2024503718A5 - - Google Patents

Info

Publication number
JP2024503718A5
JP2024503718A5 JP2023543203A JP2023543203A JP2024503718A5 JP 2024503718 A5 JP2024503718 A5 JP 2024503718A5 JP 2023543203 A JP2023543203 A JP 2023543203A JP 2023543203 A JP2023543203 A JP 2023543203A JP 2024503718 A5 JP2024503718 A5 JP 2024503718A5
Authority
JP
Japan
Prior art keywords
breast cancer
positive
negative
cdk4
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503718A (ja
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed filed Critical
Priority claimed from PCT/US2022/012631 external-priority patent/WO2022155543A1/en
Publication of JP2024503718A publication Critical patent/JP2024503718A/ja
Publication of JP2024503718A5 publication Critical patent/JP2024503718A5/ja
Pending legal-status Critical Current

Links

JP2023543203A 2021-01-15 2022-01-14 乳がんを治療するための薬学的組成物及びその使用方法 Pending JP2024503718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/151,108 2021-01-15
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (2)

Publication Number Publication Date
JP2024503718A JP2024503718A (ja) 2024-01-26
JP2024503718A5 true JP2024503718A5 (https=) 2025-01-21

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543203A Pending JP2024503718A (ja) 2021-01-15 2022-01-14 乳がんを治療するための薬学的組成物及びその使用方法

Country Status (10)

Country Link
EP (1) EP4277613A4 (https=)
JP (1) JP2024503718A (https=)
KR (1) KR20230163362A (https=)
CN (1) CN116981451A (https=)
AU (1) AU2022208712A1 (https=)
BR (1) BR112023014247A2 (https=)
CA (1) CA3205212A1 (https=)
IL (1) IL304467A (https=)
MX (1) MX2023008375A (https=)
WO (1) WO2022155543A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) * 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
MX389702B (es) * 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Similar Documents

Publication Publication Date Title
JP2024503718A5 (https=)
JP6553059B2 (ja) Hbv感染の治療のための併用療法
JP2024521979A5 (https=)
RU2015104780A (ru) Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm)
JP2009536620A5 (https=)
JP2020506951A5 (https=)
JP2022514315A5 (https=)
JP2006514098A5 (https=)
JP2006511486A5 (https=)
JP2009506119A5 (https=)
JP2017530984A5 (https=)
RU93058534A (ru) Применение производных тетрагидрокарбазола в качестве антагонистов 5-нт*001 рецептора, производные тетрагидрокарбазола, способ их получения, способ лечения и фармацевтическая композиция
JP2015532295A5 (https=)
JP2006506369A5 (https=)
JP2020519606A5 (https=)
JP2020531530A5 (https=)
JP2020533352A5 (https=)
JP2023510835A5 (https=)
JP2022505841A5 (https=)
CA2477737A1 (en) Multi-substituted selective androgen receptor modulators and methods of use thereof
JP2011509309A5 (https=)
JP2006516286A5 (https=)
JPWO2021060453A5 (https=)
JP2022521955A5 (https=)
JP2023552610A5 (https=)